Oncopeptides has formally opened sEAPort, its open-label expanded access program allowing adults with triple-refractory multiple myeloma to access the investigational medicine melflufen (melphalan flufenamide) before its approval. sEAPort (NCT04534322) is available to patients in the U.S. who tried at least two prior lines of therapy and failed to respond to at least one proteasome inhibitor, one immunomodulatory agent (IMiD), and one anti-CD38 monoclonal antibody. The program is expected to enroll 100 to 200 adults at up to…
You must be logged in to read/download the full post.
The post Melflufen Open to Select Adults With Advanced Multiple Myeloma in US appeared first on BioNewsFeeds.